# Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

Source: https://onco.cc/trials/nct07432295/  
OnCo record `nct07432295` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Nivolumab, FLOT, CAPOX in metastatic cancer, run by I-Mab Biopharma US Limited, now recruiting.

## Summary

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) is a phase 2 interventional study registered as NCT07432295 by I-Mab Biopharma US Limited, with 180 participants planned, started 2026-02-11 and due to reach its primary completion in 2030-03. Interventions recorded: Givastomig, Nivolumab, 5Fluorouracil, Leucovorin, Oxaliplatin. Conditions listed: Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07432295
- Phase: 2
- Setting: A Randomized, Multicenter, Open-Label, Phase 2 Study of Givastomig (TJ033721) in Combination With Nivolumab and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated CLDN18.2 Positive and PD-1L Positive Locally Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma
- Sponsor: I-Mab Biopharma US Limited
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT07432295: https://clinicaltrials.gov/study/NCT07432295

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)](https://onco.cc/drugs/flot/), [Nivolumab](https://onco.cc/drugs/nivolumab/)

---
JSON: https://onco.cc/api/v1/entities/nct07432295.json